https://www.selleckchem.com/pr....oducts/poly-l-lysine
ue to non-ESBL-EC. This phenomenon may be attributed to timely and effective antibiotic treatment, but the initial empiric therapy with second- or third-line antibiotics in non-ESBL-EC BSI should be corrected. The outbreak of a novel coronavirus disease 2019 (COVID-19) is currently ongoing worldwide. A proportion of COVID-19 patients progress rapidly to acute respiratory failure. We aimed to build a model to predict the risk of developing severe pneumonia in patients with COVID-19 in the early stage. Data from patients who were co
Like
Comment
Share